PTC Therapeutics, Inc. (PTC), a South Plainfield, NJ-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes, completed a $30m financing.
Backers include long-term investors Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors.
The company intends to use the capital to continue late-stage clinical development of ataluren in nonsense mutation Duchenne and Becker muscular dystrophy and nonsense mutation cystic fibrosis.
Led by CEO Stuart W. Peltz, Ph.D., PTC Therapeutics has an internal pipeline that addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases.
FinSMEs
23/07/2012